Metformin modulates FJX1 via upregulation of Hsa-miR-1306-3p to suppress colon adenocarcinoma viability

Metformin modulates FJX1 via upregulation of Hsa-miR-1306-3p to suppress colon adenocarcinoma viability

Abstract Metformin, widely used for the treatment of type 2 diabetes, has recently gained attention for its potential anticancer properties. Several studies have shown that metformin treatment inhibits cell viability in colon adenocarcinoma (COAD); however, the research related to the tumor-node-met...

Full description

Saved in:
Bibliographic Details
Main Authors: Jung-min Kim, Hae Jin Shin, Woo Ryung Kim, Eun Gyung Park, Du Hyeong Lee, Yun Ju Lee, Hyeon-su Jeong, Hyun-Young Roh, Ho Jeong Kwon, Yung Hyun Choi, Sun-Hee Leem, Heui-Soo Kim
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Scientific Reports
Subjects:
Metformin
Hsa-miR-1306-3p
Colon adenocarcinoma (COAD)
FJX1
TNM stages
Online Access:https://doi.org/10.1038/s41598-025-91022-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-91022-y

Similar Items